Incidence, prevention and management of severe infections in patients undergoing therapy for chronic lymphocytic leukemia.

IF 2.3 4区医学 Q2 HEMATOLOGY

Expert Review of Hematology Pub Date : 2025-06-21 DOI:10.1080/17474086.2025.2523552

Arianna Bevilacqua, Alessandro Cellini, Francesco Angotzi, Andrea Serafin, Federica Mazzetto, Nicolò Danesin, Francesco Piazza, Livio Trentin, Andrea Visentin

{"title":"Incidence, prevention and management of severe infections in patients undergoing therapy for chronic lymphocytic leukemia.","authors":"Arianna Bevilacqua, Alessandro Cellini, Francesco Angotzi, Andrea Serafin, Federica Mazzetto, Nicolò Danesin, Francesco Piazza, Livio Trentin, Andrea Visentin","doi":"10.1080/17474086.2025.2523552","DOIUrl":null,"url":null,"abstract":"Introduction: Chronic Lymphocytic Leukemia (CLL) is a disease marked by high infectious risk due to a combination of patient, disease and treatment-related factors. As a new landscape in the therapeutic panorama is emerging with the introduction of novel agents, it is essential to understand their impact on the incidence of infectious events and consequently what prevention and management strategies should be introduced.Areas covered: We searched the PUBMED database considering peer-reviewed papers published between January 2013 and January 2025 that reported on at least 100 patients and provided detailed information on infectious complications. Retrospective studies, pooled analyses, and commentaries were excluded.Expert opinion: Infections are a considerable adverse effect that can occur in CLL patients under treatment, with their incidence being influenced by intrinsic biology of the disease, the number of prior lines of therapy, and treatment duration. This being considered, the initiation of fixed duration therapy combined with the use of preventive measures, such as immunoglobulin replacement therapy and vaccination programs, should be preferred whenever feasible.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-13"},"PeriodicalIF":2.3000,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2025.2523552","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Chronic Lymphocytic Leukemia (CLL) is a disease marked by high infectious risk due to a combination of patient, disease and treatment-related factors. As a new landscape in the therapeutic panorama is emerging with the introduction of novel agents, it is essential to understand their impact on the incidence of infectious events and consequently what prevention and management strategies should be introduced.

Areas covered: We searched the PUBMED database considering peer-reviewed papers published between January 2013 and January 2025 that reported on at least 100 patients and provided detailed information on infectious complications. Retrospective studies, pooled analyses, and commentaries were excluded.

Expert opinion: Infections are a considerable adverse effect that can occur in CLL patients under treatment, with their incidence being influenced by intrinsic biology of the disease, the number of prior lines of therapy, and treatment duration. This being considered, the initiation of fixed duration therapy combined with the use of preventive measures, such as immunoglobulin replacement therapy and vaccination programs, should be preferred whenever feasible.

查看原文本刊更多论文

慢性淋巴细胞白血病治疗中严重感染的发生率、预防和管理。

慢性淋巴细胞白血病（Chronic Lymphocytic Leukemia， CLL）是一种因患者、疾病和治疗相关因素共同作用而具有高传染性的疾病。随着新药物的引入，治疗全景中出现了新的景观，了解它们对感染事件发生率的影响以及应该引入哪些预防和管理策略是至关重要的。涵盖领域：我们检索了PUBMED数据库，考虑了2013年1月至2025年1月期间发表的同行评议论文，这些论文报告了至少100名患者，并提供了感染并发症的详细信息。回顾性研究、汇总分析和评论被排除在外。专家意见：在接受治疗的CLL患者中，感染是一个相当大的不良反应，其发生率受疾病的内在生物学特性、先前治疗的数量和治疗时间的影响。考虑到这一点，在可行的情况下，应优先采用固定时间的治疗，并结合使用预防措施，如免疫球蛋白替代疗法和疫苗接种计划。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Hematology HEMATOLOGY-

CiteScore

4.70

自引率

3.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.